T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
A range of emerging therapeutic approaches for the treatment of cancer aim to induce or augment endogenous T cell responses. Chimeric antigen receptor (CAR) T cell therapy (CTT) is one such approach that utilises the patient’s own T cells, engineered ex vivo to target cell surface antigens, to eliminate haematological malignancies. Despite mediating high rates of responses in some clinical trials, this approach can be limited by dysfunctional T cells if they are present at high frequencies either in the starting material from the patient or the CAR T cell product. The fitness of an individual’s T cells, driven by age, chronic infection, disease burden and cancer treatment, is therefore likely to be a crucial limiting factor of CTT. Currently, T cell dysfunction and its impact on CTT is not specifically quantified when patients are considering the therapy. Here, we review our current understanding of T cell fitness for CTT, how fitness may be impacted by age, chronic infection, malignancy, and treatment. Finally, we explore options to specifically tailor clinical decision-making and the CTT protocol for patients with more extensive dysfunction to improve treatment efficacy. A greater understanding of T cell fitness throughout a patient’s treatment course could ultimately be used to identify patients likely to achieve favourable CTT outcomes and improve methods for T cell collection and CTT delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Functional analysis demonstrated enhanced per-cell cytotoxic activity in LNP-transfected cells, reduced expression of exhaustion markers (TIM-3 and LAG-3), robust activation indicating preserved functional fitness,68 higher migratory capacity, and a controlled cytokine profile compared to electroporated T cells.”
From Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation (2026) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Chronic Inflammation (Inflammaging) and Its Potential Contribution to Age-Associated Diseases
Franceschi, C., & Campisi, J. (2014) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glu057 · Cited by 3,891
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560
Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M., Arnason, J., Mehta, A., Purev, E., Maloney, D. G., Andreadis, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31366-0 · Cited by 2,430
Research works printed but not linked: 71
- Schuster, 2017, Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas, N Eng J Med, 377, 2545, 10.1056/NEJMOA1708566 · DOI · Paper page
- Harris, 2018, Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition Domains, J Immunol, 200, 10.4049/jimmunol.1700236 · DOI · Paper page
- Hirayama, 2019, High Rate of Durable Complete Remission in Follicular Lymphoma After CD19 CAR-T Cell Immunotherapy, Blood, 134, 636, 10.1182/BLOOD.2019000905 · DOI · Paper page
- Klebanoff, 2005, Central Memory Self/Tumor-Reactive CD8+ T Cells Confer Superior Antitumor Immunity Compared With Effector Memory T Cells, PNAS, 102, 10.1073/pnas.0503726102 · DOI · Paper page
- Gattinoni, 2005, Removal of Homeostatic Cytokine Sinks by Lymphodepletion Enhances the Efficacy of Adoptively Transferred Tumor-Specific CD8+ T Cells, J Exp Med, 202, 10.1084/jem.20050732 · DOI · Paper page
- Ghafouri, 2021, Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-Cell Lymphomas: A Single-Institution Experience, Clin Lymph Myel Leuk, 1, 10.1016/J.CLML.2021.07.002 · DOI
- Turtle, 2017, Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib, J Clin Oncol, 35, 3010, 10.1200/JCO.2017.72.8519 · DOI · Paper page
- Suen, 2016, Multiple Myeloma Causes Clonal T-Cell Immunosenescence: Identification of Potential Novel Targets for Promoting Tumour Immunity and Implications for Checkpoint Blockade, Leukemia, 30, 10.1038/leu.2016.84 · DOI · Paper page
- Cooke, 2020, Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells, Front Immunol, 11, 10.3389/fimmu.2020.02153 · DOI
- Reiser, 2016, Effector, Memory, and Dysfunctional CD8+ T Cell Fates in the Antitumor Immune Response, J Immunol Res, 2016, 10.1155/2016/8941260 · DOI · Paper page
- Geginat, 2003, Proliferation and Differentiation Potential of Human CD8+ Memory T-Cell Subsets in Response to Antigen or Homeostatic Cytokines, Blood, 101, 10.1182/BLOOD-2002-11-3577 · DOI · Paper page
- Wherry, 2004, Memory CD8 T-Cell Differentiation During Viral Infection, J Virol, 78, 10.1128/jvi.78.11.5535-5545.2004 · DOI · Paper page
- Weng, 2009, CD28– T Cells: Their Role in the Age-Associated Decline of Immune Function, Trends Immunol, 30, 306, 10.1016/J.IT.2009.03.013 · DOI · Paper page
- Tay, 2020, Revisiting the Role of CD4+ T Cells in Cancer Immunotherapy—New Insights Into Old Paradigms, Cancer Gene Ther 2020 28:1, 28, 5, 10.1038/s41417-020-0183-x · DOI · Paper page
- Cullen, 2019, CD4 + T Help Promotes Influenza Virus-Specific CD8 + T Cell Memory by Limiting Metabolic Dysfunction, PNAS, 116, 10.1073/pnas.1808849116 · DOI
- Ahrends, 2017, CD4+ T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness, Immunity, 47, 848, 10.1016/J.IMMUNI.2017.10.009 · DOI · Paper page
- Aarntzen, 2013, Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell–Based Vaccination, Cancer Res, 73, 19, 10.1158/0008-5472.CAN-12-1127 · DOI · Paper page
- Sukumar, 2016, Mitochondrial Membrane Potential Identifies Cells With Enhanced Stemness for Cellular Therapy, Cell Metab, 23, 63, 10.1016/J.CMET.2015.11.002 · DOI · Paper page
- Levine, 2021, Single-Cell Analysis by Mass Cytometry Reveals Metabolic States of Early-Activated CD8+ T Cells During the Primary Immune Response, Immunity, 54, 829, 10.1016/J.IMMUNI.2021.02.018 · DOI
- Chang, 2014, Molecular Regulation of Effector and Memory T Cell Differentiation, Nat Immunol, 15, 10.1038/NI.3031 · DOI · Paper page
- Hinrichs, 2011, Human Effector CD8+ T Cells Derived From Naive Rather Than Memory Subsets Possess Superior Traits for Adoptive Immunotherapy, Blood, 117, 10.1182/blood-2010-05-286286 · DOI · Paper page
- Garfall, 2019, T-Cell Phenotypes Associated With Effective CAR T-Cell Therapy in Postinduction vs Relapsed Multiple Myeloma, Blood Adv, 3, 10.1182/bloodadvances.2019000600 · DOI · Paper page
- Berger, 2008, Adoptive Transfer of Effector CD8+ T Cells Derived From Central Memory Cells Establishes Persistent T Cell Memory in Primates, J Clin Invest, 118, 294, 10.1172/JCI32103 · DOI · Paper page
- Chen, 2021, Integrative Bulk and Single-Cell Profiling of Premanufacture T-Cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-Cell Therapy, Cancer Discovery, 11, 10.1158/2159-8290.CD-20-1677 · DOI · Paper page
- Korell, 2020, Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients With Relapsed/Refractory NHL or ALL, Cells, 9, 10.3390/cells9051225 · DOI
- McBride, 2017, Imbalance in the Game of T Cells: What can the CD4/CD8 T-Cell Ratio Tell Us About HIV and Health, PloS Pathog, 13, 1, 10.1371/journal.ppat.1006624 · DOI · Paper page
- Rivière, 2000, Retroviral-Mediated Gene Transfer in Primary Murine and Human T-Lymphocytes, Mol Biotech, 15, 10.1385/MB:15:2:133 · DOI
- Kong, 2021, BET Bromodomain Protein Inhibition Reverses Chimeric Antigen Receptor Extinction and Reinvigorates Exhausted T Cells in Chronic Lymphocytic Leukemia BET Bromodomain Protein Inhibition Reverses Chimeric Antigen Receptor Extinction and Reinvigorates Exhaust, J Clin Invest, 131, 1, 10.1172/JCI145459 · DOI
- Sommermeyer, 2016, Chimeric Antigen Receptor-Modified T Cells Derived From Defined CD8+ and CD4+ Subsets Confer Superior Antitumor Reactivity In Vivo, Leukemia, 30, 492, 10.1038/LEU.2015.247 · DOI · Paper page
- Abramson, 2021, Cytokine Release Syndrome and Neurological Event Costs in Lisocabtagene Maraleucel-Treated Patients in the TRANSCEND NHL 001 Trial, Blood Adv, 5, 10.1182/bloodadvances.2020003531 · DOI
- Hinrichs, 2008, IL-2 and IL-21 Confer Opposing Differentiation Programs to CD8+ T Cells for Adoptive Immunotherapy, Blood, 111, 5326, 10.1182/BLOOD-2007-09-113050 · DOI · Paper page
- Sabatino, 2016, Generation of Clinical-Grade CD19-Specific CAR-Modified CD8+ Memory Stem Cells for the Treatment of Human B-Cell Malignancies, Blood, 128, 519, 10.1182/BLOOD-2015-11-683847 · DOI · Paper page
- Mueller, 2017, Cellular Kinetics of CTL019 in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia and Chronic Lymphocytic Leukemia, Blood, 130, 2317, 10.1182/BLOOD-2017-06-786129 · DOI · Paper page
- Awasthi, 2020, Tisagenlecleucel Cellular Kinetics, Dose, and Immunogenicity in Relation to Clinical Factors in Relapsed/Refractory DLBCL, Blood Adv, 4, 560, 10.1182/BLOODADVANCES.2019000525 · DOI
- Hong, 2018, CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30+ and CD30– Embryonal Carcinoma via Antigen-Dependent and Fas/FasL Interactions, Can Immunol Res, 6, 1274, 10.1158/2326-6066.CIR-18-0065 · DOI
- Davenport, 2018, Chimeric Antigen Receptor T Cells Form Nonclassical and Potent Immune Synapses Driving Rapid Cytotoxicity, PNAS, 115, E2068, 10.1073/PNAS.1716266115 · DOI · Paper page
- Weber, 2021, Transient “Rest” Restores Functionality in Exhausted CAR-T Cells via Epigenetic Remodeling, Science, 372, eaba1786, 10.1126/SCIENCE.ABA1786 · DOI · Paper page
- Salter, 2018, Phosphoproteomic Analysis of Chimeric Antigen Receptor Signaling Reveals Kinetic and Quantitative Differences That Affect Cell Function, Sci Signal, 11, eaba1786, 10.1126/SCISIGNAL.AAT6753 · DOI · Paper page
- Montecino-Rodriguez, 2019, Lymphoid-Biased Hematopoietic Stem Cells Are Maintained With Age and Efficiently Generate Lymphoid Progeny, Stem Cell Rep, 12, 10.1016/j.stemcr.2019.01.016 · DOI · Paper page
- Becklund, 2016, The Aged Lymphoid Tissue Environment Fails to Support Naive T Cell Homeostasis, Sci Rep, 6, 1, 10.1038/srep30842 · DOI · Paper page
- Goronzy, 2007, Aging and T-Cell Diversity, Exp Gerontol, 42, 400, 10.1016/J.EXGER.2006.11.016 · DOI · Paper page
- Quinn, 2020, Metabolic Characteristics of CD8+ T Cell Subsets in Young and Aged Individuals are Not Predictive of Functionality, Nat Comms, 11, 10.1038/S41467-020-16633-7 · DOI
- Cannon, 2010, Review of Cytomegalovirus Seroprevalence and Demographic Characteristics Associated With Infection, Rev Med Virol, 20, 10.1002/rmv.655 · DOI · Paper page
- Pipeling, 2008, Differential CMV-Specific CD8+ Effector T Cell Responses in the Lung Allograft Predominate Over the Blood During Human Primary Infection, J Immunol, 181, 546, 10.4049/JIMMUNOL.181.1.546 · DOI
- Gkrania-Klotsas, 2012, Higher Immunoglobulin G Antibody Levels Against Cytomegalovirus Are Associated With Incident Ischemic Heart Disease in the Population-Based EPIC-Norfolk Cohort, J Infect Dis, 206, 10.1093/INFDIS/JIS620 · DOI · Paper page
- O’Hara, 2012, Memory T Cell Inflation: Understanding Cause and Effect, Trends Immunol, 33, 84, 10.1016/j.it.2011.11.005 · DOI
- Luo, 2018, The Impact of Inflationary Cytomegalovirus-Specific Memory T Cells on Anti-Tumour Immune Responses in Patients With Cancer, Immunol, 155, 294, 10.1111/imm.12991 · DOI
- Burger, 2013, Impact of Interleukin-6 in Hematological Malignancies, Transf Med Hemother, 40, 10.1159/000354194 · DOI · Paper page
- Prabhala, 2010, Elevated IL-17 Produced by TH17 Cells Promotes Myeloma Cell Growth and Inhibits Immune Function in Multiple Myeloma, Blood, 115, 10.1182/blood-2009-10-246660 · DOI · Paper page
- Roessner, 2020, T-Cells in Chronic Lymphocytic Leukemia: Guardians or Drivers of Disease, Leukemia, 34, 10.1038/s41375-020-0873-2 · DOI
- Elston, 2020, Increased Frequency of CD4+PD-1+HLA-DR+ T Cells is Associated With Disease Progression in CLL, Brit J Haematol, 188, 10.1111/bjh.16260 · DOI
- Riches, 2013, T Cells From CLL Patients Exhibit Features of T-Cell Exhaustion But Retain Capacity for Cytokine Production, Blood, 121, 10.1182/blood-2012-09-457531 · DOI · Paper page
- Mackall, 2000, Prolonged CD4 Depletion After Sequential Autologous Peripheral Blood Progenitor Cell Infusions in Children and Young Adults, Blood, 96, 10.1182/blood.v96.2.754 · DOI
- Hakim, 1997, Constraints on CD4 Recovery Postchemotherapy in Adults: Thymic Insufficiency and Apoptotic Decline of Expanded Peripheral CD4 Cells, Blood, 90, 10.1182/blood.v90.9.3789 · DOI · Paper page
- Young, 2001, Impact of Aging on Immune Modulation by Tumor, Can Immunol Immuno, 50, 10.1007/s002620100203 · DOI
- Neelapu, 2020, Outcomes of Older Patients in ZUMA-1, a Pivotal Study of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma, Blood, 135, 10.1182/BLOOD.2019004162 · DOI
- Lin, 2021, Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma, N Eng J Med, 10.1056/NEJMoa2024850 · DOI · Paper page
- Caulier, 2021, Epidemiological Landscape of Young Multiple Myeloma Patients Diagnosed Earlier Than 40 Years: The French Experience, Blood, 10.1182/BLOOD.2021011285 · DOI
- Tuazon, 2019, Factors Affecting Lymphocyte Collection Efficiency for the Manufacture of Chimeric Antigen Receptor T Cells in Adults With B Cell Malignancies, Transfusion, 59, 1773, 10.1111/TRF.15178 · DOI
- Westin, 2021, Efficacy and Safety of CD19-Directed CAR-T Cell Therapies in Patients With Relapsed/Refractory Aggressive B-Cell Lymphomas: Observations From the JULIET, ZUMA-1, and TRANSCEND Trials, Am J Hematol, 96, 10.1002/AJH.26301 · DOI · Paper page
- Guha, 2017, Frontline Science: Functionally Impaired Geriatric CAR-T Cells Rescued by Increased α5β1 Integrin Expression, J Leuk Biol, 102, 10.1189/jlb.5hi0716-322rr · DOI
- Zettler, 2021, Real-World Adverse Events Associated With CAR T-Cell Therapy Among Adults Age ≥ 65 Years, J Ger Oncol, 12, 10.1016/J.JGO.2020.07.006 · DOI
- Fiorenza, 2020, Value and Affordability of CAR T-Cell Therapy in the United States, Bone Mar Transpl, 55, 10.1038/s41409-020-0956-8 · DOI
- Mohty, 2021, Current Combinatorial CAR T Cell Strategies With Bruton Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors, Bone Mar Transpl, 2021, 1, 10.1038/s41409-021-01420-9 · DOI
- Caruso, 2019, Shortened Ex Vivo Manufacturing Time of EGFRvIII-Specific Chimeric Antigen Receptor (CAR) T Cells Reduces Immune Exhaustion and Enhances Antiglioma Therapeutic Function, J Neuro Oncol, 145, 10.1007/s11060-019-03311-y · DOI
- John, 2013, Blockade of PD-1 Immunosuppression Boosts CAR T-Cell Therapy, Oncoimmunology, 2, 10.4161/ONCI.26286 · DOI · Paper page
- Depil, 2020, ‘Off-The-Shelf’ Allogeneic CAR T Cells: Development and Challenges, Nat Rev Drug Discovery, 19, 10.1038/s41573-019-0051-2 · DOI · Paper page
- Gauthier, 2020, Feasibility and Efficacy of CD19-Targeted CAR T Cells With Concurrent Ibrutinib for CLL After Ibrutinib Failure, Blood, 135, 1650, 10.1182/BLOOD.2019002936 · DOI · Paper page
- Bai, 2015, Enhancement of the In Vivo Persistence and Antitumor Efficacy of CD19 Chimeric Antigen Receptor T Cells Through the Delivery of Modified TERT mRNA, Cell Discovery, 1, 1, 10.1038/celldisc.2015.40 · DOI
- Guedan, 2014, ICOS-Based Chimeric Antigen Receptors Program Bipolar TH17/ TH1 Cells, Blood, 124, 10.1182/blood-2013-10-535245 · DOI · Paper page
- Song, 2012, CD27 Costimulation Augments the Survival and Antitumor Activity of Redirected Human T Cells In Vivo, Blood, 119, 696, 10.1182/blood-2011-03-344275 · DOI · Paper page
Cited by
Garfall, A. L., Cohen, A. D., Susanibar-Adaniya, S. P., Hwang, W.-T., Vogl, D. T., Waxman, A. J., Lacey, S. F., Gonzalez, V. E., Fraietta, J. A., Gupta, M., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-22-0074 · Cited by 83
The paths and challenges of “off-the-shelf” CAR-T cell therapy: an overview of clinical trials
Moradi, V., Omidkhoda, A., & Ahmadbeigi, N. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115888 · Cited by 80
Picht, S., Farrera-Sal, M., Hiller, A. L., Brumhard, S., Klaas, A. M., Schulenberg, S., Friedrich, R., Scholz, C., Hemmerling, L., Simon, D. N., et al. (2026) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2026.102929 · Cited by 7
Metadata
- Authors
- Mehta, P. H., Fiorenza, S., Koldej, R. M., Jaworowski, A., Ritchie, D. S., & Quinn, K. M.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2021-11-25
- Volume
- 12
- ISSN
- 1664-3224
- Cited by
- 95
- References
- 42
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy. https://app.cochat.ai/papers/10.3389/fimmu.2021.780442
- The paper
- Mehta, P. H., Fiorenza, S., Koldej, R. M., Jaworowski, A., Ritchie, D. S., & Quinn, K. M. (2021). T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2021.780442
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.